133 related articles for article (PubMed ID: 31450889)
1. Chimeras of Cell-Penetrating Peptides Demonstrate Synergistic Improvement in Antisense Efficacy.
Fadzen CM; Holden RL; Wolfe JM; Choo ZN; Schissel CK; Yao M; Hanson GJ; Pentelute BL
Biochemistry; 2019 Sep; 58(38):3980-3989. PubMed ID: 31450889
[TBL] [Abstract][Full Text] [Related]
2. Helix-Stabilized Cell-Penetrating Peptides for Delivery of Antisense Morpholino Oligomers: Relationships among Helicity, Cellular Uptake, and Antisense Activity.
Takada H; Tsuchiya K; Demizu Y
Bioconjug Chem; 2022 Jul; 33(7):1311-1318. PubMed ID: 35737901
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
4. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.
Youngblood DS; Hatlevig SA; Hassinger JN; Iversen PL; Moulton HM
Bioconjug Chem; 2007; 18(1):50-60. PubMed ID: 17226957
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
Haque US; Yokota T
Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
[TBL] [Abstract][Full Text] [Related]
6. Perfluoroaryl Bicyclic Cell-Penetrating Peptides for Delivery of Antisense Oligonucleotides.
Wolfe JM; Fadzen CM; Holden RL; Yao M; Hanson GJ; Pentelute BL
Angew Chem Int Ed Engl; 2018 Apr; 57(17):4756-4759. PubMed ID: 29479836
[TBL] [Abstract][Full Text] [Related]
7. The heparin-binding domain of HB-EGF as an efficient cell-penetrating peptide for drug delivery.
Luo Z; Cao XW; Li C; Wu MD; Yang XZ; Zhao J; Wang FJ
J Pept Sci; 2016 Nov; 22(11-12):689-699. PubMed ID: 27739168
[TBL] [Abstract][Full Text] [Related]
8. Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency.
Yin H; Boisguerin P; Moulton HM; Betts C; Seow Y; Boutilier J; Wang Q; Walsh A; Lebleu B; Wood MJ
Mol Ther Nucleic Acids; 2013 Sep; 2(9):e124. PubMed ID: 24064708
[TBL] [Abstract][Full Text] [Related]
9. Label-Free Confocal Raman Mapping of Transportan in Melanoma Cells.
Cosme PJ; Ye J; Sears S; Wojcikiewicz EP; Terentis AC
Mol Pharm; 2018 Mar; 15(3):851-860. PubMed ID: 29397737
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
11. Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.
Stoodley J; Miraz DS; Jad Y; Fischer M; Wood MJA; Varela MA
Methods Mol Biol; 2023; 2587():209-237. PubMed ID: 36401033
[TBL] [Abstract][Full Text] [Related]
12. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
13. Cell-Penetrating d-Peptides Retain Antisense Morpholino Oligomer Delivery Activity.
Schissel CK; Farquhar CE; Malmberg AB; Loas A; Pentelute BL
ACS Bio Med Chem Au; 2022 Apr; 2(2):150-160. PubMed ID: 37101743
[TBL] [Abstract][Full Text] [Related]
14. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
15. Cell penetration: scope and limitations by the application of cell-penetrating peptides.
Reissmann S
J Pept Sci; 2014 Oct; 20(10):760-84. PubMed ID: 25112216
[TBL] [Abstract][Full Text] [Related]
16. Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.
Burki U; Keane J; Blain A; O'Donovan L; Gait MJ; Laval SH; Straub V
Nucleic Acid Ther; 2015 Oct; 25(5):275-84. PubMed ID: 26176274
[TBL] [Abstract][Full Text] [Related]
17. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
18. Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide.
Yeoh YQ; Amin A; Cuic B; Tomas D; Turner BJ; Shabanpoor F
Biomed Pharmacother; 2024 Jun; 175():116737. PubMed ID: 38749176
[TBL] [Abstract][Full Text] [Related]
19. Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers.
Moulton HM
Methods Mol Biol; 2012; 867():407-14. PubMed ID: 22454076
[TBL] [Abstract][Full Text] [Related]
20. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B
J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
